Powering the answers to the toughest questions in cancer

M2GEN connects patients, providers, and researchers to fundamentally change the way cancer is studied and treated

Learn More

Purpose-driven and Patient-centric

Next Generation

Impacting Healthcare for the Next Generation

M2GEN is an oncology-focused health informatics solutions company with the mission to help patients get access to the best treatments by leveraging clinical and molecular data to accelerate the discovery, development, and delivery of tailored and more personalized therapies. M2GEN's approach is to transform cancer care through application of genome analysis of patient-derived tumor specimens, and translating novel molecular findings combined with clinical insights for the actualization of precision oncology therapeutics and diagnostics. 

Learn More

Next Generation

Accelerating Precision Medicine

M2GEN partners with 18 of the nation’s leading cancer centers, through the Oncology Research Information Exchange Network® (ORIEN), to deliver oncology informatics-based solutions to accelerate therapy discovery, development and delivery of precision medicine. M2GEN is one of the only companies to ensure that patient data has been granted through consent

M2GEN utilizes the IRB-approved protocol, Total Cancer Care®, that allows for enhanced patient engagement through the ability to re-contact patients and facilitates linkages across disparate sources of data, creating a research ecosystem which can significantly benefit patients and improve patient care.

By leveraging a large clinical and molecular database, interpreted through sophisticated data science, we help researchers solve some of the most complex problems in cancer.

Understand how M2GEN is transforming cancer research through oncology informatics-based solutions

See More

Globally Recognized Expertise

Looking for patient genomic and real-world data?

See how M2GEN is aggregating and analyzing healthcare data for actionable insights

Request For Proposal

Submit Your RFP

Our Latest Developments

  1. Whole Exome Sequencing Versus RNA Sequencing

  2. M2GEN Announces New Collaboration with Merck to Advance Cancer Therapies

  3. CD&R, Merck GHI, and McKesson Ventures Invest in Innovative Oncology Data and Informatics Company M2GEN

If you like how M2GEN is fundamentally advancing how cancer is studied and treated, join us!

See More